Search results
Results from the WOW.Com Content Network
On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with ...
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. Novocure (NASDAQ: NVCR) and its international partner Zai ...
Novocure plans to submit marketing application to the U.S. Food and Drug Administration in the second half of 2023 based on the data. Novocure's shares fell 34.2% to a more than three-year low of ...
(Reuters) -Novocure's therapy met the main goal of a late-stage trial of slowing the progression of cancer to the brain in patients with a type of lung cancer, the company said on Wednesday ...
Novocure’s new flagship facility will provide space for its growing employee base within the greater Portsmouth region, according to company representatives. Novocure touts its Tumor Treating Fields
Novocure Ltd. (Nasdaq: NVCR) was founded in 2000. As of December 2020, Novocure Ltd. has over 1000 employees and makes hundreds of millions of dollars in annual sales. Israeli Professor Yoram Palti, professor of physiology and biophysics at the Israel Institute of Technology, is the company's founder and chief technology officer.
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
We ended the quarter with a record 4,113 active patients on therapy, breaking the 4,000-patient threshold for the first time. This helped us deliver 22% year-over-year top-line growth.